• Consensus Rating: Moderate Buy
  • Consensus Price Target: $405.80
  • Forecasted Upside: 11.30%
  • Number of Analysts: 20
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 17 Buy Ratings
  • 0 Strong Buy Ratings
$364.60
▲ +7.46 (2.09%)

This chart shows the closing price for SYK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Stryker Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYK

Analyst Price Target is $405.80
▲ +11.30% Upside Potential
This price target is based on 20 analysts offering 12 month price targets for Stryker in the last 3 months. The average price target is $405.80, with a high forecast of $450.00 and a low forecast of $360.00. The average price target represents a 11.30% upside from the last price of $364.60.

This chart shows the closing price for SYK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 20 investment analysts is to moderate buy stock in Stryker. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/24/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/22/2024
  • 0 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 0 sell ratings
11/21/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 17 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Truist FinancialBoost TargetHold ➝ Hold$380.00 ➝ $409.00
12/12/2024Needham & Company LLCBoost TargetBuy ➝ Buy$409.00 ➝ $442.00
12/11/2024CitigroupBoost TargetBuy ➝ Buy$411.00 ➝ $450.00
12/11/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$400.00 ➝ $425.00
12/11/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$405.00 ➝ $427.00
12/2/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$370.00 ➝ $445.00
10/31/2024CitigroupBoost TargetBuy ➝ Buy$406.00 ➝ $411.00
10/31/2024BarclaysBoost TargetOverweight ➝ Overweight$402.00 ➝ $418.00
10/30/2024BTIG ResearchBoost TargetBuy ➝ Buy$383.00 ➝ $394.00
10/30/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$360.00 ➝ $400.00
10/30/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$380.00 ➝ $420.00
10/30/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$386.00 ➝ $400.00
10/30/2024Truist FinancialBoost TargetHold ➝ Hold$370.00 ➝ $380.00
10/30/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$375.00 ➝ $420.00
10/30/2024UBS GroupBoost TargetNeutral ➝ Neutral$366.00 ➝ $370.00
10/30/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$381.00 ➝ $405.00
10/30/2024Evercore ISIBoost TargetOutperform ➝ Outperform$380.00 ➝ $384.00
10/30/2024Needham & Company LLCBoost TargetBuy ➝ Buy$393.00 ➝ $409.00
10/30/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$378.00 ➝ $405.00
10/14/2024BTIG ResearchBoost TargetBuy ➝ Buy$374.00 ➝ $383.00
10/14/2024Truist FinancialBoost TargetHold ➝ Hold$345.00 ➝ $370.00
10/1/2024Evercore ISIBoost TargetOutperform ➝ Outperform$365.00 ➝ $380.00
9/10/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$380.00 ➝ $380.00
9/10/2024Wolfe ResearchInitiated CoverageOutperform$405.00
8/28/2024BTIG ResearchBoost TargetBuy ➝ Buy$360.00 ➝ $374.00
8/1/2024BarclaysBoost TargetOverweight ➝ Overweight$374.00 ➝ $402.00
8/1/2024Truist FinancialLower TargetHold ➝ Hold$364.00 ➝ $345.00
8/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$392.00 ➝ $393.00
7/31/2024BTIG ResearchLower TargetBuy ➝ Buy$372.00 ➝ $360.00
7/31/2024Stifel NicolausLower TargetBuy ➝ Buy$375.00 ➝ $365.00
7/31/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$386.00 ➝ $386.00
7/31/2024UBS GroupBoost TargetNeutral ➝ Neutral$351.00 ➝ $366.00
7/15/2024BTIG ResearchBoost TargetBuy ➝ Buy$369.00 ➝ $372.00
7/15/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$345.00 ➝ $350.00
7/2/2024Evercore ISILower TargetOutperform ➝ Outperform$370.00 ➝ $365.00
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$372.00
5/22/2024Needham & Company LLCUpgradeHold ➝ Buy$392.00
5/2/2024BarclaysBoost TargetOverweight ➝ Overweight$372.00 ➝ $376.00
5/1/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$364.00 ➝ $381.00
5/1/2024Roth MkmBoost TargetBuy ➝ Buy$348.00 ➝ $405.00
5/1/2024UBS GroupBoost TargetNeutral ➝ Neutral$339.00 ➝ $351.00
5/1/2024Piper SandlerBoost TargetOverweight ➝ Overweight$375.00 ➝ $380.00
5/1/2024Stifel NicolausBoost TargetBuy ➝ Buy$350.00 ➝ $375.00
5/1/2024Needham & Company LLCReiterated RatingHold
5/1/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$367.00 ➝ $378.00
5/1/2024BTIG ResearchBoost TargetBuy ➝ Buy$366.00 ➝ $369.00
4/15/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$360.00 ➝ $386.00
4/11/2024TD CowenBoost TargetBuy ➝ Buy$365.00 ➝ $400.00
4/4/2024Evercore ISIBoost TargetOutperform ➝ Outperform$340.00 ➝ $370.00
4/3/2024CitigroupBoost TargetBuy ➝ Buy$362.00 ➝ $406.00
2/15/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$360.00
1/31/2024CitigroupBoost TargetBuy ➝ Buy$340.00 ➝ $362.00
1/31/2024Truist FinancialBoost TargetHold ➝ Hold$330.00 ➝ $345.00
1/31/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$345.00 ➝ $360.00
1/31/2024Roth MkmBoost TargetBuy ➝ Buy$345.00 ➝ $348.00
1/31/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$336.00 ➝ $364.00
1/31/2024Canaccord Genuity GroupUpgradeHold ➝ Buy$360.00
1/31/2024Canaccord Genuity GroupUpgradeHold ➝ Buy$315.00 ➝ $360.00
1/12/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$315.00 ➝ $345.00
12/22/2023Truist FinancialBoost TargetHold ➝ Hold$300.00 ➝ $320.00
12/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$300.00 ➝ $320.00
11/9/2023UBS GroupBoost TargetNeutral ➝ Neutral$289.00 ➝ $297.00
11/9/2023Roth MkmReiterated RatingBuy ➝ Buy$345.00
11/6/2023Truist FinancialBoost TargetHold ➝ Hold$270.00 ➝ $300.00
10/20/2023Roth MkmInitiated CoverageBuy$345.00
10/2/2023CitigroupLower TargetBuy ➝ Buy$342.00 ➝ $330.00
9/5/2023Bank of AmericaUpgradeNeutral ➝ Buy$310.00 ➝ $315.00
8/17/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$325.00
8/7/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$295.00 ➝ $300.00
8/7/2023BarclaysBoost TargetOverweight ➝ Overweight$321.00 ➝ $335.00
7/19/2023Truist FinancialBoost Target$300.00 ➝ $310.00
7/17/2023BTIG ResearchBoost Target$313.00 ➝ $331.00
7/12/2023Royal Bank of CanadaBoost Target$315.00 ➝ $325.00
5/25/2023ArgusBoost Target$285.00 ➝ $310.00
5/2/2023Deutsche Bank AktiengesellschaftBoost Target$260.00 ➝ $292.00
5/2/2023Royal Bank of CanadaBoost Target$288.00 ➝ $315.00
5/2/2023Stifel NicolausBoost Target$280.00 ➝ $330.00
5/2/2023JPMorgan Chase & Co.Boost Target$285.00 ➝ $315.00
5/2/2023Jefferies Financial GroupBoost Target$320.00 ➝ $345.00
5/2/2023BTIG ResearchBoost Target$299.00 ➝ $313.00
5/2/2023Piper SandlerBoost Target$280.00 ➝ $310.00
5/2/2023Robert W. BairdBoost Target$287.00 ➝ $315.00
5/2/2023Wells Fargo & CompanyBoost Target$285.00 ➝ $336.00
5/2/2023BarclaysBoost Target$314.00 ➝ $321.00
4/23/2023Sanford C. BernsteinBoost Target$275.00 ➝ $336.00
4/17/2023Truist FinancialBoost TargetHold$275.00 ➝ $300.00
4/17/2023BTIG ResearchBoost TargetBuy$281.00 ➝ $299.00
4/17/2023Loop CapitalBoost TargetBuy$290.00 ➝ $312.00
4/11/2023BarclaysBoost Target$283.00 ➝ $314.00
4/3/2023CitigroupBoost TargetBuy$290.00 ➝ $326.00
3/31/2023Jefferies Financial GroupBoost TargetBuy$292.00 ➝ $320.00
3/28/2023Canaccord Genuity GroupReiterated RatingHold$250.00
3/28/2023UBS GroupInitiated CoverageNeutral$287.00
2/21/2023ArgusBoost TargetBuy$270.00 ➝ $285.00
2/2/2023BarclaysBoost TargetOverweight$265.00 ➝ $283.00
2/1/2023Morgan StanleyBoost TargetEqual Weight$260.00 ➝ $280.00
2/1/2023BTIG ResearchBoost TargetBuy$268.00 ➝ $281.00
2/1/2023Loop CapitalBoost TargetBuy$245.00 ➝ $290.00
2/1/2023Wells Fargo & CompanyBoost TargetOverweight$281.00 ➝ $285.00
2/1/2023Canaccord Genuity GroupBoost TargetHold$220.00 ➝ $250.00
2/1/2023Piper SandlerBoost TargetOverweight$250.00 ➝ $280.00
2/1/2023Truist FinancialBoost TargetHold$257.00 ➝ $275.00
2/1/2023Royal Bank of CanadaBoost TargetOutperform$284.00 ➝ $288.00
2/1/2023Robert W. BairdBoost TargetOutperform$240.00 ➝ $287.00
2/1/2023CitigroupBoost TargetBuy$282.00 ➝ $290.00
1/25/2023KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
1/9/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$240.00 ➝ $284.00
1/6/2023Morgan StanleyBoost TargetEqual Weight$220.00 ➝ $260.00
1/4/2023BarclaysBoost Target$257.00 ➝ $265.00
1/3/2023Evercore ISIBoost Target$265.00
12/21/2022BTIG ResearchBoost Target$232.00 ➝ $268.00
12/20/2022Truist FinancialBoost TargetHold$230.00 ➝ $252.00
12/14/2022CowenBoost Target$233.00 ➝ $283.00
12/14/2022CowenBoost Target$233.00 ➝ $283.00
12/12/2022Wells Fargo & CompanyBoost TargetOverweight$248.00 ➝ $281.00
12/12/2022CitigroupBoost Target$249.00 ➝ $282.00
12/1/2022BarclaysBoost TargetOverweight$239.00 ➝ $257.00
11/4/2022Truist FinancialBoost Target$230.00
11/1/2022Royal Bank of CanadaLower TargetSector Perform$255.00 ➝ $240.00
11/1/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$225.00 ➝ $220.00
11/1/2022Wells Fargo & CompanyBoost TargetOverweight$237.00 ➝ $248.00
10/17/2022BarclaysInitiated CoverageOverweight$239.00
10/17/2022BTIG ResearchLower TargetBuy$238.00 ➝ $232.00
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$270.00
10/10/2022Piper SandlerLower Target$260.00 ➝ $250.00
10/5/2022CitigroupLower Target$255.00 ➝ $246.00
9/14/2022Piper SandlerBoost TargetOverweight$250.00 ➝ $260.00
9/6/2022BTIG ResearchLower TargetBuy$244.00 ➝ $238.00
7/28/2022Edward JonesUpgradeHold ➝ Buy
7/27/2022Truist FinancialBoost TargetOutperform$220.00
7/27/2022Robert W. BairdLower TargetOutperform ➝ Outperform$297.00 ➝ $240.00
7/27/2022Piper SandlerLower TargetOverweight$290.00 ➝ $250.00
7/22/2022Truist FinancialLower Target$213.00
7/22/2022CowenLower TargetOutperform$305.00 ➝ $233.00
7/21/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$285.00 ➝ $205.00
7/18/2022BTIG ResearchLower TargetBuy$278.00 ➝ $244.00
7/18/2022Stifel NicolausLower Target$285.00 ➝ $245.00
7/15/2022Morgan StanleyLower TargetEqual Weight$270.00 ➝ $220.00
7/11/2022Bank of AmericaDowngradeBuy ➝ Neutral
5/17/2022CitigroupLower Target$310.00 ➝ $280.00
5/2/2022Truist FinancialLower Target$296.00 ➝ $280.00
4/29/2022Piper SandlerLower Target$315.00 ➝ $290.00
4/18/2022BTIG ResearchBoost Target$273.00 ➝ $278.00
4/12/2022Truist FinancialInitiated CoverageHold$296.00
3/16/2022Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$288.00 ➝ $295.00
3/15/2022Evercore ISIReiterated RatingOutperform$284.00
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ Buy
1/31/2022Morgan StanleyLower TargetEqual Weight$305.00 ➝ $275.00
1/28/2022Leerink PartnersLower TargetOutperform$300.00 ➝ $285.00
1/28/2022BTIG ResearchLower TargetBuy$280.00 ➝ $273.00
1/28/2022CitigroupLower Target$300.00 ➝ $290.00
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$305.00
1/4/2022Piper SandlerUpgradeNeutral ➝ Overweight$250.00 ➝ $315.00
12/9/2021Royal Bank of CanadaInitiated CoverageSector Perform$278.00
12/6/2021Loop CapitalInitiated CoverageBuy$305.00
11/19/2021Morgan StanleyBoost TargetOverweight$295.00 ➝ $305.00
10/29/2021Robert W. BairdReiterated RatingBuy$301.00
10/29/2021Piper SandlerBoost TargetNeutral$250.00 ➝ $255.00
10/22/2021Leerink PartnersReiterated RatingOutperform
9/14/2021Raymond JamesInitiated CoverageMarket Perform
7/29/2021ArgusBoost TargetBuy$280.00 ➝ $320.00
7/28/2021Truist FinancialBoost TargetHold$250.00 ➝ $275.00
7/28/2021Morgan StanleyBoost TargetOverweight$280.00 ➝ $300.00
7/28/2021Leerink PartnersBoost TargetOutperform$290.00 ➝ $300.00
7/28/2021Credit Suisse GroupBoost TargetOutperform$291.00 ➝ $311.00
7/28/2021OppenheimerBoost TargetMarket Perform$273.00 ➝ $288.00
7/28/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform$248.00 ➝ $310.00
7/28/2021Needham & Company LLCReiterated RatingHold
7/28/2021Robert W. BairdBoost TargetOutperform$292.00 ➝ $305.00
7/28/2021CitigroupBoost TargetBuy$303.00 ➝ $310.00
7/28/2021Piper SandlerBoost TargetNeutral$250.00 ➝ $255.00
7/20/2021Leerink PartnersReiterated RatingOutperform
6/28/2021Credit Suisse GroupReiterated RatingBuy$291.00
6/1/2021Evercore ISIUpgradeIn-Line ➝ Outperform$260.00 ➝ $285.00
5/24/2021BarclaysInitiated CoverageUnderweight$280.00
4/28/2021OppenheimerBoost Target$240.00 ➝ $273.00
4/28/2021Truist FinancialBoost Target$245.00 ➝ $255.00
4/28/2021CitigroupBoost Target$264.00 ➝ $303.00
4/28/2021Morgan StanleyBoost TargetOverweight$265.00 ➝ $280.00
4/28/2021Wells Fargo & CompanyBoost TargetOverweight$265.00 ➝ $300.00
4/28/2021Raymond JamesBoost TargetOutperform$255.00 ➝ $290.00
4/28/2021CowenBoost TargetOutperform$255.00 ➝ $279.00
4/28/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$251.00 ➝ $285.00
4/28/2021Robert W. BairdBoost TargetOutperform$265.00 ➝ $292.00
2/24/2021JPMorgan Chase & Co.Boost TargetOverweight$245.00 ➝ $265.00
1/28/2021Credit Suisse GroupLower TargetOutperform ➝ Outperform$278.00 ➝ $273.00
1/28/2021Morgan StanleyLower TargetOverweight$272.00 ➝ $265.00
1/28/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$228.00 ➝ $251.00
1/28/2021Raymond JamesBoost TargetOutperform$240.00 ➝ $255.00
1/28/2021Needham & Company LLCReiterated RatingHold
1/6/2021Truist FinancialBoost Target$210.00 ➝ $245.00
1/6/2021Credit Suisse GroupBoost TargetOutperform$253.00 ➝ $278.00
1/4/2021GuggenheimInitiated CoverageNeutral
12/31/2020BTIG ResearchBoost TargetBuy$234.00 ➝ $252.00
12/15/2020Morgan StanleyBoost TargetOverweight$225.00 ➝ $272.00
11/12/2020Robert W. BairdBoost TargetOutperform$243.00 ➝ $258.00
10/30/2020Smith Barney CitigroupBoost Target$232.00 ➝ $240.00
10/30/2020Leerink PartnersBoost TargetOutperform$225.00 ➝ $235.00
10/30/2020Credit Suisse GroupBoost TargetOutperform$243.00 ➝ $253.00
10/12/2020Raymond JamesBoost TargetOutperform$220.00 ➝ $240.00
10/6/2020Northland SecuritiesInitiated CoverageMarket Perform$225.00
9/28/2020Wells Fargo & CompanyBoost TargetOverweight$222.00 ➝ $232.00
9/11/2020Wolfe ResearchInitiated CoverageMarket Perform$230.00
7/31/2020UBS GroupBoost TargetNeutral$202.00 ➝ $215.00
7/31/2020Morgan StanleyBoost TargetOverweight$215.00 ➝ $225.00
7/31/2020Leerink PartnersBoost TargetOutperform$215.00 ➝ $225.00
7/31/2020Credit Suisse GroupBoost TargetOutperform$237.00 ➝ $243.00
7/31/2020Needham & Company LLCReiterated RatingHold
7/31/2020OppenheimerReiterated RatingHold$215.00
7/31/2020CitigroupBoost TargetBuy$227.00 ➝ $232.00
7/15/2020Leerink PartnersReiterated RatingOutperform
5/11/2020ArgusLower TargetBuy$240.00 ➝ $230.00
5/1/2020CitigroupBoost TargetBuy$200.00 ➝ $215.00
5/1/2020CfraLower TargetStrong-Buy$234.00 ➝ $231.00
5/1/2020Wells Fargo & CompanyBoost TargetOverweight$201.00 ➝ $205.00
5/1/2020Morgan StanleyBoost TargetOverweight$210.00 ➝ $215.00
5/1/2020Stifel NicolausBoost TargetBuy$145.00 ➝ $205.00
5/1/2020UBS GroupLower TargetNeutral$230.00 ➝ $202.00
5/1/2020OppenheimerReiterated RatingHold$200.00
5/1/2020Credit Suisse GroupBoost TargetOutperform$229.00 ➝ $237.00
5/1/2020Deutsche Bank AktiengesellschaftLower TargetBuy$243.00 ➝ $228.00
4/22/2020CowenLower TargetOutperform$240.00 ➝ $220.00
4/15/2020JPMorgan Chase & Co.Lower TargetOverweight$240.00 ➝ $210.00
4/13/2020Raymond JamesLower TargetOutperform$240.00 ➝ $205.00
4/13/2020BarclaysDowngradeEqual Weight ➝ Underweight$155.00
4/1/2020Wells Fargo & CompanyLower TargetOverweight$243.00 ➝ $201.00
4/1/2020The Goldman Sachs GroupDowngradeBuy ➝ Sell$248.00 ➝ $150.00
3/27/2020Morgan StanleyLower TargetOverweight$250.00 ➝ $210.00
3/27/2020CitigroupLower TargetBuy$235.00 ➝ $200.00
3/25/2020Credit Suisse GroupLower TargetOutperform$247.00 ➝ $162.00
3/24/2020Stifel NicolausLower TargetBuy$250.00 ➝ $145.00
3/6/2020Credit Suisse GroupLower TargetOutperform$255.00 ➝ $247.00
3/4/2020CitigroupInitiated CoverageBuy$235.00
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$248.00
1/30/2020BTIG ResearchReiterated RatingBuy
1/29/2020Cantor FitzgeraldReiterated RatingNeutral
1/29/2020Stifel NicolausBoost TargetBuy$245.00 ➝ $250.00
1/29/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$239.00 ➝ $243.00
1/29/2020Robert W. BairdBoost TargetOutperform$242.00 ➝ $248.00
1/29/2020Morgan StanleyBoost TargetOverweight$242.00 ➝ $250.00
1/7/2020SunTrust BanksInitiated CoverageHold$217.00
1/7/2020Piper SandlerDowngradeOverweight ➝ Neutral$210.00
1/7/2020Piper Sandler CompaniesDowngradeOverweight ➝ Neutral$210.00
1/3/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$179.00
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform
12/30/2019BTIG ResearchBoost TargetBuy$228.00 ➝ $236.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.33 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 37 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/25/2024
  • 32 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/24/2024
  • 23 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/24/2024
  • 35 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/23/2024
  • 43 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/22/2024
  • 26 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/22/2024
  • 81 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/21/2024
  • 93 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/21/2024

Current Sentiment

  • 93 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Stryker logo
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Read More

Today's Range

Now: $364.60
Low: $356.00
High: $364.80

50 Day Range

MA: $374.66
Low: $352.82
High: $392.15

52 Week Range

Now: $364.60
Low: $288.90
High: $398.20

Volume

3,146,655 shs

Average Volume

1,269,702 shs

Market Capitalization

$138.99 billion

P/E Ratio

39.08

Dividend Yield

0.86%

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Stryker?

The following sell-side analysts have issued reports on Stryker in the last year: Barclays PLC, BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Roth Mkm, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for SYK.

What is the current price target for Stryker?

0 Wall Street analysts have set twelve-month price targets for Stryker in the last year. Their average twelve-month price target is $405.80, suggesting a possible upside of 11.3%. Citigroup Inc. has the highest price target set, predicting SYK will reach $450.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $360.00 for Stryker in the next year.
View the latest price targets for SYK.

What is the current consensus analyst rating for Stryker?

Stryker currently has 3 hold ratings and 17 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SYK.

What other companies compete with Stryker?

How do I contact Stryker's investor relations team?

Stryker's physical mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company's listed phone number is (269) 385-2600 and its investor relations email address is [email protected]. The official website for Stryker is www.strykercorp.com. Learn More about contacing Stryker investor relations.